Does Blue Cross Blue Shield of North Carolina Cover Dupixent?

What Is Dupixent and Why Does Coverage Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, two cytokines central to type-2 inflammatory disease. The FDA first approved dupilumab in March 2017 for moderate-to-severe atopic dermatitis in adults and has since expanded its label across six additional indications. [1]

Because Dupixent is a specialty biologic, it carries one of the highest price tags in dermatology and pulmonology. The 2024 wholesale acquisition cost runs approximately $3,300, $3,600 per syringe, which translates to roughly $39,000, $43,000 per year for the standard atopic dermatitis dosing regimen of 300 mg every two weeks. [2] At that price point, insurance coverage is not optional for most patients. Whether BCBS NC pays depends on your specific plan document, the indication being treated, and whether prior authorization criteria are met.

How Dupixent Is Classified on BCBS NC Formularies

BCBS NC places dupilumab on Specialty Tier 4 or Tier 5 on most of its commercial and Marketplace formularies. Specialty tier cost-sharing typically means a coinsurance of 20 to 35% rather than a flat copay, which can translate to $600, $1,200 per injection out-of-pocket before any assistance program applies. The State Health Plan (the plan covering North Carolina state employees) has historically placed Dupixent on its specialty drug list with prior authorization required and may require mail-order dispensing through a specialty pharmacy network.

Medical Benefit vs. Pharmacy Benefit

Dupixent can be billed under either the pharmacy benefit (patient self-injects, fills at specialty pharmacy) or the medical benefit (administered in-office, billed under a J-code). BCBS NC generally processes self-administered Dupixent under the pharmacy benefit. When a physician administers the loading dose in the office, it may process under the medical benefit with different cost-sharing. Confirming which benefit applies to your situation before the first fill prevents unexpected billing surprises.

FDA-Approved Indications BCBS NC Will Consider for Coverage

BCBS NC aligns its coverage criteria closely with FDA-approved labeling. Requests for off-label use face significantly higher denial rates. The currently approved indications are as follows. [1]

Atopic Dermatitis

The FDA approved dupilumab for moderate-to-severe atopic dermatitis in adults in 2017, extended coverage to adolescents (12 to 17 years) in 2019, children 6 to 11 years in 2020, and infants and children aged 6 months to 5 years in 2022. [1] BCBS NC coverage criteria for atopic dermatitis typically require:

• A confirmed diagnosis of moderate-to-severe disease, often defined by an Investigator Global Assessment (IGA) score of 3 or 4 or an Eczema Area and Severity Index (EASI) score ≥16.
• Documented inadequate response, intolerance, or contraindication to at least one topical corticosteroid (medium-to-high potency) used for a minimum of 4 to 8 weeks.
• In some BCBS NC plan variants, documented trial of a topical calcineurin inhibitor such as tacrolimus or pimecrolimus.

The phase 3 SOLO 1 and SOLO 2 trials (combined N=1,379) showed that 36 to 38% of adults receiving dupilumab 300 mg every two weeks achieved an IGA score of 0 or 1 at 16 weeks, compared with 8 to 10% on placebo (P<0.001). [3] BCBS NC medical directors frequently cite this level of evidence when approving atopic dermatitis requests.

Moderate-to-Severe Asthma

For add-on maintenance therapy in moderate-to-severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma, BCBS NC typically requires documentation of:

• Baseline blood eosinophil count ≥150 cells/µL or fractional exhaled nitric oxide (FeNO) ≥25 ppb.
• Inadequate control on a medium-to-high-dose inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA).
• Spirometry confirming airflow obstruction (FEV1 <80% predicted).

The LIBERTY ASTHMA QUEST trial (N=1,902) demonstrated that dupilumab 200 mg every two weeks reduced severe exacerbation rates by 47.7% in patients with baseline eosinophils ≥150 cells/µL compared with placebo. [4] BCBS NC plan guidelines reference eosinophil thresholds drawn directly from this dataset.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

BCBS NC covers dupilumab for CRSwNP as add-on maintenance therapy in adults with inadequate response to intranasal corticosteroids. Most plan documents also require at least one prior sinonasal surgery or documentation that surgery is contraindicated. The LIBERTY NP SINUS-24 and SINUS-52 trials (N=276 and N=448, respectively) showed significant reductions in nasal polyp score and nasal congestion at 24 weeks. [5]

Eosinophilic Esophagitis, Prurigo Nodularis, and Chronic Rhinosinusitis Without Nasal Polyps (Prurigo Nodularis / PND)

The FDA approved dupilumab for eosinophilic esophagitis (EoE) in adults and adolescents ≥12 years in May 2022, for prurigo nodularis (PN) in September 2022, and for chronic rhinosinusitis without nasal polyps (CRSwNP/PND) in June 2024. [1] Coverage for these newer indications is less uniform across BCBS NC plan types and may require a peer-to-peer review or specialist attestation letter.

Prior Authorization: What BCBS NC Requires Step by Step

Prior authorization (PA) is mandatory for Dupixent across every BCBS NC plan type. Denials on the first submission occur in roughly 30% of specialty biologic requests industry-wide, most commonly because the PA form is missing required laboratory values or treatment history documentation. [6]

Information Your Prescriber Must Submit

A complete PA submission to BCBS NC for dupilumab typically requires:

1. ICD-10 diagnosis code confirming the covered indication.
2. Disease severity documentation (IGA/EASI score for AD, spirometry for asthma, endoscopy report for EoE).
3. Step therapy records showing dates, doses, and duration of prior treatments and the specific reason each failed (lack of efficacy, adverse event, or contraindication).
4. Most recent relevant labs (eosinophil count for asthma, biopsy eosinophil count for EoE).
5. A note from the treating board-certified dermatologist, allergist, or otolaryngologist confirming medical necessity.

BCBS NC targets a 3-business-day turnaround for standard PA requests and 72 hours for urgent requests under North Carolina insurance law requirements. [7]

Step Therapy and How to Document Failure

Step therapy remains the most common reason for initial PA denials. For atopic dermatitis, BCBS NC typically requires at least 4 to 8 weeks of a mid-to-high-potency topical corticosteroid such as triamcinolone 0.1% or clobetasol 0.05%. Documenting that the patient completed the course, had a follow-up visit, and still had an IGA ≥3 satisfies most plan criteria.

The American Academy of Dermatology (AAD) 2023 guidelines state: "Dupilumab is recommended for patients 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies." [8] Including this guideline language verbatim in the PA letter strengthens the submission.

What Happens After a BCBS NC Denial?

A denial is not the end of the road. North Carolina law entitles members to both an internal appeal and an external independent review. [7]

Internal Appeal

You have 180 days from the denial notice to file an internal appeal with BCBS NC. The appeal should include:

• A peer-reviewed letter from the treating physician explaining why standard step-therapy alternatives are not appropriate for this specific patient.
• Published clinical guidelines (AAD for AD, GINA 2024 for asthma, ACG guidelines for EoE). [8, 9, 10]
• Any relevant comorbidity documentation (e.g., ocular complications of AD that make additional topical steroids inappropriate).

Peer-to-Peer Review

Before filing a formal appeal, the prescribing physician can request a peer-to-peer phone call with the BCBS NC medical reviewer. This call typically takes 15 to 20 minutes and succeeds more often than written appeals alone when the physician can directly address the specific criterion that triggered the denial.

External Independent Review

If the internal appeal fails, North Carolina law mandates an external independent review by an organization not affiliated with BCBS NC. The external reviewer issues a binding decision within 45 days (standard) or 72 hours (expedited for urgent cases). [7] Independent reviews overturn insurer denials approximately 40% of the time for specialty biologics, according to a 2021 analysis of state external review databases. [11]

Cost and Copay Assistance Options

Even with active BCBS NC coverage, specialty tier cost-sharing can leave patients with hundreds or thousands of dollars in annual out-of-pocket costs.

Dupixent MyWay Copay Card

Sanofi and Regeneron offer the Dupixent MyWay program for commercially insured patients. Eligible patients with commercial insurance (not Medicare, Medicaid, or any federal program) may pay as little as $0 per month, with a program maximum benefit of up to $13,000 per year. Patients can enroll at the Dupixent MyWay website or by calling 1-844-DUPIXENT. [12]

This program does not apply to BCBS NC State Health Plan members who receive coverage through the North Carolina State employees benefit, as that plan is self-funded and typically classified as a federal-adjacent benefit, making most commercial copay cards non-applicable. Those patients should inquire about Sanofi's patient assistance program (PAP) separately.

Patient Assistance Program

For patients who are uninsured, underinsured, or whose income falls below 600% of the federal poverty level, Sanofi's patient assistance program may provide Dupixent at no cost. Applications require proof of income and a prescriber attestation. [12]

North Carolina Pharmaceutical Assistance Program

North Carolina does not have a state-run general pharmaceutical assistance program equivalent to those in some other states, so Dupixent patients cannot rely on a state-funded fallback. The primary assistance routes remain the manufacturer's programs above.

Special Populations and Plan-Specific Nuances

Pediatric Patients (Ages 6 Months to 17 Years)

BCBS NC commercial plans generally follow FDA age-specific labeling for pediatric atopic dermatitis. However, the prior authorization criteria for children under 6 years are stricter on some BCBS NC Marketplace plans, often requiring specialist (board-certified pediatric dermatologist) attestation. The LIBERTY AD PRESCHOOL trial (N=162) demonstrated that dupilumab 300 mg every 4 weeks in children aged 6 months to 5 years achieved an IGA 0/1 response in 28.0% vs. 4.1% placebo at week 16 (P<0.001). [13] Citing this trial in a pediatric PA submission supports medical necessity effectively.

BCBS NC Medicare Advantage Plans

BCBS NC Medicare Advantage plans follow CMS formulary rules. Dupixent appears on the specialty tier of most BCBS NC Medicare Advantage formularies. The Medicare copay card restriction means the Dupixent MyWay card cannot be used. Medicare Part D Extra Help (Low Income Subsidy) reduces cost-sharing for eligible beneficiaries. Patients should also check whether their plan has a specialty drug exception process allowing placement on a lower tier. [14]

State Health Plan (North Carolina State Employees)

The North Carolina State Health Plan is self-insured and administered by BCBS NC. The plan uses its own drug formulary and may apply different step therapy requirements than commercial fully-insured products. As of 2024, the State Health Plan requires prior authorization for dupilumab and mandates documentation of failure of at least two conventional topical therapies for atopic dermatitis before approval.

The BCBS NC Formulary Exception Process

If dupilumab is denied because your specific plan's formulary does not include it, you may request a formulary exception. A formulary exception asks the plan to cover a non-formulary drug on the basis that all formulary alternatives are clinically inappropriate.

Successful formulary exception requests typically include:

• A prescriber letter citing a contraindication or documented intolerance to all formulary-tier alternatives (e.g., cyclosporine, methotrexate, azathioprine for atopic dermatitis).
• Clinical evidence that formulary alternatives pose unacceptable risk (e.g., methotrexate in a patient planning pregnancy).
• Reference to the AAD's statement that dupilumab has a favorable safety profile compared with immunosuppressant systemic agents. [8]

The decision framework below summarizes the coverage pathway a patient and prescriber should follow when pursuing BCBS NC Dupixent coverage:

Step 1. Confirm the FDA-approved indication and severity threshold match plan criteria. Step 2. Document step-therapy completion with specific dates, products, doses, and outcomes. Step 3. Submit a complete PA with all required labs and specialist notes. Step 4. If denied, request a peer-to-peer review within 5 business days of denial. Step 5. File a formal internal appeal within 180 days if peer-to-peer does not resolve the denial. Step 6. Request external independent review if the internal appeal is upheld. Step 7. Enroll in Dupixent MyWay while coverage is pending to prevent treatment interruption.

Clinical Evidence Supporting Coverage Approval

Insurance reviewers respond to trial-level data. Including the following evidence in PA letters and appeals improves approval rates.

Atopic Dermatitis Outcomes

The CHRONOS trial (N=740) evaluated dupilumab plus topical corticosteroids over 52 weeks. At week 52, 39% of patients receiving dupilumab 300 mg every two weeks plus TCS achieved an IGA of 0 or 1, compared with 12% on TCS alone (P<0.001). [15] This long-term dataset is particularly useful for demonstrating sustained benefit and justifying continued coverage after year one.

A 2022 real-world registry analysis published in JAMA Dermatology (N=2,525 patients across 9 countries) reported that 59% of patients with moderate-to-severe atopic dermatitis treated with dupilumab achieved an EASI score <7 (clear or almost clear) at 6 months. [16]

Asthma Outcomes

The TRAVERSE open-label extension of the LIBERTY ASTHMA trials followed patients for up to 96 weeks. Patients originally randomized to dupilumab maintained a 59% reduction in annualized severe exacerbation rate relative to placebo-period baseline. [17] For OCS-dependent asthma, dupilumab reduced oral corticosteroid dose by 70% in the VENTURE trial (N=210) vs. 42% placebo (P<0.001). [18]

Eosinophilic Esophagitis

In the part B cohort of the EoE LIBERTY trial (N=80), dupilumab 300 mg weekly produced histologic remission (<15 eosinophils/hpf) in 47.4% of patients at 24 weeks vs. 2.4% on placebo. [19] The ACG 2024 clinical guidelines now include dupilumab as a recommended therapeutic option for EoE in patients with inadequate response to proton-pump inhibitors and topical corticosteroids. [10]

Monitoring and Renewal Requirements

BCBS NC approvals for Dupixent are not permanent. Most plans issue initial approvals for 6 to 12 months and require a renewal PA demonstrating treatment response.

For atopic dermatitis renewals, BCBS NC typically asks for:

• Documentation of at least a 50% improvement in EASI score or a reduction in IGA by ≥1 point from baseline.
• A note confirming the patient is tolerating treatment and has not developed significant adverse events.

Common adverse events reported in trials include injection-site reactions (occurring in approximately 10% of patients), conjunctivitis (occurring in approximately 8 to 10% of patients in AD trials), and nasopharyngitis. [3] Documenting that adverse events are managed and have not caused treatment discontinuation supports renewal.

The Dupixent prescribing information notes that conjunctivitis and keratitis were reported more frequently in atopic dermatitis patients (approximately 10%) than in asthma patients (approximately 2%), a distinction worth noting when writing renewal letters for AD patients who develop ocular symptoms. [2]